Seeking Alpha
01 Jan 2026, 07:13 UTC · 37w ago
Verdict
Headline takes no side. We score VKTX +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Viking Therapeutics' oral GLP-1 candidate VK2735 achieved 12.2% weight loss at the highest dose over 13 weeks in Phase 2 trials.
More positive than 99% of claims this week
The company is progressing with a 78-week Phase 3 'Vanquish' trial for its injectable version of the drug.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 92% of claims this week
Management has identified a Phase 3 dosing range of 20-75 mg for the oral candidate to balance efficacy and tolerability.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Strong Phase 2 results for its oral obesity drug candidate show efficacy matching or exceeding peers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
7h ago
+18.6%
Price agrees with the score
$41.74 vs $35.18 close before publication (Dec 31) · not market-adjusted
VKTX chart →
